GoAI
Get started
QT Imaging Holdings, Inc. logo

QT Imaging Holdings, Inc.

QTI

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$2.91

+$0.13 · +4.68%

Aug 21, 4:00 PM ET

QTI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

65

Undervalued

Momentum

17

Strong Down

Sentiment

51

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

QT Imaging Holdings, Inc. is dedicated to the research, development, and manufacturing of advanced automated systems for breast imaging. These innovative devices are engineered to generate high-resolution ultrasound images utilizing transmission technology. The company's core product, the QT Ultrasound Breast Scanner, offers comprehensive reflection-mode and transmission-mode visualization of a patient's breast tissue. Established in 2011, QT Imaging Holdings, Inc. maintains its headquarters in Novato, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Raluca Dinu
Listed since
Mar 5, 2024
Employees
32

Market position

Day range

Current $2.91

52-week range

Current $2.91

Open
$2.82
Previous close
$2.78
Volume
15.29K
0.33× average
Average volume
46.91K
Average daily volume
Market cap
40.07M USD
Beta
-0.01
Market reference 1
50-day average
$3.3135
-12.18% below average
200-day average
$5.3292
-45.40% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
58.69M USD
P/E (TTM)
-2.05×
P/B (TTM)
19.22×
P/S (TTM)
1.42×
EV / EBITDA
-3.2×
Earnings yield
-32.99%
Free cash flow yield
-14.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
39.56%
Operating margin
-17.45%
Net margin
-65.31%
Return on equity
-327.12%
Return on assets
-91.58%
Return on invested capital
-28.41%

Financial health

Debt / equity
1.93×
Current ratio
2.81×
Altman Z-score
-2.16
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1571%-4496%-10563%-16630%Gross margin, FY2021: 28.64%Gross margin, FY2023: -234.50%Gross margin, FY2024: 54.11%Gross margin, FY2025: 45.36%Operating margin, FY2021: -1929.03%Operating margin, FY2023: -12409.76%Operating margin, FY2024: -249.60%Operating margin, FY2025: -23.45%Net margin, FY2021: -1482.99%Net margin, FY2023: -15113.25%Net margin, FY2024: -184.17%Net margin, FY2025: -111.40%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 28.64%. Gross margin FY2023 -234.50%. Gross margin FY2024 54.11%. Gross margin FY2025 45.36%. Operating margin FY2021 -1929.03%. Operating margin FY2023 -12409.76%. Operating margin FY2024 -249.60%. Operating margin FY2025 -23.45%. Net margin FY2021 -1482.99%. Net margin FY2023 -15113.25%. Net margin FY2024 -184.17%. Net margin FY2025 -111.40%.

Income trends

Revenue

18.93M USD+287.91%

Operating income

−4.44M USD+63.56%

Net income

−21.08M USD-134.65%
Income trends across reported periods22.93M USD6.92M USD−9.08M USD−25.08M USDRevenue, FY2021: 365.15K USDRevenue, FY2023: 40.36K USDRevenue, FY2024: 4.88M USDRevenue, FY2025: 18.93M USDOperating income, FY2021: −7.04M USDOperating income, FY2022: −4.28M USDOperating income, FY2023: −5.01M USDOperating income, FY2024: −12.18M USDOperating income, FY2025: −4.44M USDNet income, FY2021: −5.42M USDNet income, FY2022: −2.77M USDNet income, FY2023: −6.1M USDNet income, FY2024: −8.98M USDNet income, FY2025: −21.08M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 365.15K USD. Revenue FY2023 40.36K USD. Revenue FY2024 4.88M USD. Revenue FY2025 18.93M USD. Operating income FY2021 −7.04M USD. Operating income FY2022 −4.28M USD. Operating income FY2023 −5.01M USD. Operating income FY2024 −12.18M USD. Operating income FY2025 −4.44M USD. Net income FY2021 −5.42M USD. Net income FY2022 −2.77M USD. Net income FY2023 −6.1M USD. Net income FY2024 −8.98M USD. Net income FY2025 −21.08M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue18.93M USD4.88M USD40.36K USD—365.15K USD
Cost of goods sold10.34M USD2.24M USD134.99K USD556.93K USD260.57K USD
Gross profit8.58M USD2.64M USD−94.63K USD—104.58K USD
Research and development3.94M USD3.27M USD1.49M USD2.39M USD2.16M USD
Selling, general, and administrative9.09M USD11.55M USD3.43M USD4.28M USD4.99M USD
Operating expenses13.02M USD14.82M USD4.91M USD3.72M USD7.15M USD
Interest income——1.53M USD1.63M USD—
Interest expense2.64M USD4.5M USD544.83K USD23.1K USD192.96K USD
Depreciation and amortization131K USD230.8K USD480.69K USD651.75K USD950.73K USD
Operating income−4.44M USD−12.18M USD−5.01M USD−4.28M USD−7.04M USD
Net income−21.08M USD−8.98M USD−6.1M USD−2.77M USD−5.42M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
40%
2 beats, 3 misses, 0 met estimates
Average EPS surprise
-342.61%
5 comparable reports
Latest EPS result
-0.75
Estimate -0.22 · Miss by 240.91%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.45-0.87-1.29Q1 '25No estimateQ2 '25BeatQ3 '25No estimateQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.45, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 13, 2025: actual -0.4, estimate -1.2, surprise +66.67%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.42, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 10, 2025: actual -0.47, estimate -0.03, surprise -1466.67%, Miss. Q1 2026, reported Feb 18, 2026: actual -0.1, estimate -0.115, surprise +13.04%, Beat. Q2 2026, reported May 13, 2026: actual -0.25, estimate -0.135, surprise -85.19%, Miss. Q3 2026, reported Aug 12, 2026: actual -0.75, estimate -0.22, surprise -240.91%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.095, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.26B3.51B1.76B2.38MQ1 '25No estimateQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual 4.87B USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 13, 2025: actual 2.8M USD, estimate 2.8M USD, surprise -0.06%, Miss. Q3 2025, reported Aug 7, 2025: actual 3.66M USD, estimate 4.18M USD, surprise -12.46%, Miss. Q4 2025, reported Nov 10, 2025: actual 4.19M USD, estimate 5.35M USD, surprise -21.69%, Miss. Q1 2026, reported Feb 18, 2026: actual 8.28M USD, estimate 7.75M USD, surprise +6.77%, Beat. Q2 2026, reported May 13, 2026: actual 6.53M USD, estimate 6.45M USD, surprise +1.27%, Beat. Q3 2026, reported Aug 12, 2026: actual 7.44M USD, estimate 7.6M USD, surprise -2.17%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 11.35M USD, surprise —, Comparison unavailable.

QTI news

businesswire.com

QT Imaging Issues Mid-Year 2026 CEO Letter to Shareholders

NOVATO, Calif.--(BUSINESS WIRE)---- $QTI #BreastCancer--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through…

Read source
seekingalpha.com

QT Imaging Holdings, Inc. (QTI) Q2 2026 Earnings Call Transcript

QT Imaging Holdings, Inc. (QTI) Q2 2026 Earnings Call Transcript

Read source
businesswire.com

QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale

NOVATO, Calif.--(BUSINESS WIRE)---- $QTI #BreastCancer--QT Imaging Holding, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through…

Read source
businesswire.com

QT Imaging to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026

NOVATO, Calif.--(BUSINESS WIRE)---- $QTI #BreastCancer--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through…

Read source
businesswire.com

QT Imaging Advances Direct U.S. Commercial Strategy to Accelerate Adoption of its Breast Acoustic CT Scanner with Two Key Hires

NOVATO, Calif.--(BUSINESS WIRE)---- $QTI #BreastCancer--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through…

Read source
businesswire.com

QT Imaging Appoints Medical Imaging and Digital Health Executive Dr. Julia Albright as Chief Science Officer

NOVATO, Calif.--(BUSINESS WIRE)---- $QTI #BreastCancer--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through…

Read source

QTI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding QTI

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
663.19K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
279.01K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
87.36K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research QTI

research.disclaimer